Emily Pollock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emily Pollock has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Katie Doores
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UK
14 shared publications - Adrian Hayday
Francis Crick Institute, London, UK
13 shared publications - Ashwini Kurshan
Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London SE1 9RT, UK
13 shared publications - Austin Kulasekararaj
King's College Hospital NHS Foundation Trust Haematology London UK
13 shared publications - Bernard V. North
Wolfson Institute of Population Health, Queen Mary University of London , London
13 shared publications - Celeste Arman
Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King's College London, London, United Kingdom
13 shared publications
Latest Publications
- Open Access
- 30 July 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (9) , 2657-2666
Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial
Immunotherapy targeting the autoimmune process in type 1 diabetes (T1D) can delay the loss of β-cells but needs to have minimal adverse effects to be an adjunct to insulin in the management of T1D. Ustekinumab binds to the shared p40 subunit of interleukin (IL)-12 and IL-23, targeting development of T helper 1 cells and T helper 17 cells (TH1 and TH17 cells) implicated in the pathogenesis of T1D. We conducted a double-blind, randomized controlled trial of ustekinumab in 72 adolescents aged 12–18 years with recent-onset T1D. Treatment was well tolerated with no increase in adverse events. At 12 months, β-cell function, measured by stimulated C-peptide, was 49% higher in the intervention group (P = 0.02), meeting the prespecified primary outcome. Preservation of C-peptide correlated with the reduction of T helper cells co-secreting IL-17A and interferon-γ (TH17.1 cells, P = 0.04) and, in particular, with the reduction in a subset of TH17.1 cells co-expressing IL-2 and granulocyte–macrophage colony-stimulating factor (IL-2+ GM-CSF+ TH17.1 cells, P = 0.04). A significant fall in β-cell-targeted (proinsulin-specific) IL-17A-secreting T cells was also seen (P = 0.0003). Although exploratory, our data suggest a role for an activated subset of TH17.1 cells in T1D that can be targeted with minimal adverse effects to reduce C-peptide loss, which requires confirmation in a larger study. (International Standard Randomised Controlled Trial Number Registry: ISRCTN 14274380).
- 30 July 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (9) , 2657-2666
Open AccessUstekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial
Immunotherapy targeting the autoimmune process in type 1 diabetes (T1D) can delay the loss of β-cells but needs to have minimal adverse effects to be an adjunct to insulin in the management of T1D. Ustekinumab binds to the shared p40 subunit of interleukin (IL)-12 and IL-23, targeting development of T helper 1 cells and T helper 17 cells (TH1 and TH17 cells) implicated in the pathogenesis of T1D. We conducted a double-blind, randomized controlled trial of ustekinumab in 72 adolescents aged 12–18 years with recent-onset T1D. Treatment was well tolerated with no increase in adverse events. At 12 months, β-cell function, measured by stimulated C-peptide, was 49% higher in the intervention group (P = 0.02), meeting the prespecified primary outcome. Preservation of C-peptide correlated with the reduction of T helper cells co-secreting IL-17A and interferon-γ (TH17.1 cells, P = 0.04) and, in particular, with the reduction in a subset of TH17.1 cells co-expressing IL-2 and granulocyte–macrophage colony-stimulating factor (IL-2+ GM-CSF+ TH17.1 cells, P = 0.04). A significant fall in β-cell-targeted (proinsulin-specific) IL-17A-secreting T cells was also seen (P = 0.0003). Although exploratory, our data suggest a role for an activated subset of TH17.1 cells in T1D that can be targeted with minimal adverse effects to reduce C-peptide loss, which requires confirmation in a larger study. (International Standard Randomised Controlled Trial Number Registry: ISRCTN 14274380).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S1. Waning serological responses to SARS-CoV-2 vaccination.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S1. Waning serological responses to SARS-CoV-2 vaccination.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S4. Local and systemic effects reported within 30 days after 3rd dose of COVID-19 vaccine in patients with solid and haematological cancers and healthy controls.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S4. Local and systemic effects reported within 30 days after 3rd dose of COVID-19 vaccine in patients with solid and haematological cancers and healthy controls.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S3. Boosted serological responses and persistent T cell responses following SARS-CoV-2 vaccination dose
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S3. Boosted serological responses and persistent T cell responses following SARS-CoV-2 vaccination dose
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S2. T cell responses prior to SARS-CoV-2 vaccination dose 3.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S2. T cell responses prior to SARS-CoV-2 vaccination dose 3.